These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 33062678)

  • 1. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.
    Yan W; Liu Z; Liu J; Xia Y; Hu K; Yu J
    Biomed Res Int; 2020; 2020():4241864. PubMed ID: 33062678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
    Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
    Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.
    Khvorost D; Kendall B; Jazirehi AR
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current state and future prospects of CAR T-cell therapy for myeloid malignancies].
    Saito S
    Rinsho Ketsueki; 2024; 65(7):634-643. PubMed ID: 39098014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New targets for CAR T therapy in hematologic malignancies.
    Savani M; Oluwole O; Dholaria B
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently.
    Chen Z; Liu Y; Chen N; Xing H; Tian Z; Tang K; Rao Q; Xu Y; Wang Y; Wang M; Wang J
    Sci China Life Sci; 2023 Apr; 66(4):754-770. PubMed ID: 36251156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
    Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
    Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
    Yang Z; Wang Y
    Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in CAR T Therapy for Hematologic Malignancies.
    Freyer CW; Porter DL
    Pharmacotherapy; 2020 Aug; 40(8):741-755. PubMed ID: 32383222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.
    Guo Z; Tu S; Yu S; Wu L; Pan W; Chang N; Zhou X; Song C; Li Y; He Y
    Cancer Sci; 2021 Apr; 112(4):1357-1368. PubMed ID: 33416209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T Cell Therapy for Hematological Malignancies.
    Yang X; Wang GX; Zhou JF
    Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
    Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
    Front Immunol; 2022; 13():927153. PubMed ID: 35757715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Khan AN; Asija S; Pendhari J; Purwar R
    Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.